Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 6/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152485 | 0.84 | MAP3K9 (0.48) | CDK1MAPKAPK2KDM4EMEN1HTT | |
| SCHEMBL15467236 | 0.78 | CDK1 (0.55) | CDK1MAPKAPK2KDM4EMEN1CYP1A2 | |
| SCHEMBL6652104 | 0.78 | CDK1 (0.58) | CDK1MAPKAPK2KDM4EMEN1CYP1A2 | |
| SCHEMBL1393409 | 0.75 | GPR3 (0.43) | KDM4EMEN1HPGDHTTKMT2A | |
| SCHEMBL5381430 | 0.73 | TDP2 (0.40) | CDK1KDM4EMEN1HTTKMT2A | |
| SCHEMBL807457 | 0.73 | MAP3K9 (0.45) | KDM4EMEN1CYP1A2HPGDCYP2C19 | |
| SCHEMBL6650273 | 0.73 | PRKD1 (0.38) | CDK1MAPKAPK2KDM4EMEN1CYP1A2 | |
| SCHEMBL23878721 | 0.72 | HSD17B10 (0.45) | CDK1MAPKAPK2KDM4EMEN1KMT2A | |
| SCHEMBL13833740 | 0.69 | ILK (0.47) | KDM4EMEN1KMT2A | |
| SCHEMBL12013258 | 0.68 | GPR3 (0.52) | MEN1HPGDKMT2AGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8618107-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | CDK1 19/4885MAPKAPK2 274/4885KDM4E 1408/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | CDK1 19/4885MAPKAPK2 274/4885KDM4E 1408/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | CDK1 19/4885MAPKAPK2 274/4885KDM4E 1408/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | CDK1 19/4885MAPKAPK2 274/4885KDM4E 1408/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | CDK1 19/4885MAPKAPK2 274/4885KDM4E 1408/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CDK1 637/4885MAPKAPK2 4140/4885KDM4E 530/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | CDK1 30/4885MAPKAPK2 348/4885KDM4E 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.